(Q62063012)
Statements
A Phase 2A, Single Center, Open-label, Single-arm, 24-week Study to Evaluate the Safety, Tolerability and Efficacy of Saroglitazar Magnesium 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (English)
0 references
4 February 2019
0 references
April 2020
0 references
15
0 references
18 year
0 references
75 year
0 references